Markus Glatzel

Prof. Dr. Markus Glatzel

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Immunity
Verified
Journal Article
Closed access
SKSusanne Krasemann
Susanne Krasemann
CMCharlotte Madore
Charlotte Madore
RCRon Cialic
Ron Cialic
CBCaroline Baufeld
Caroline Baufeld
NCNarghes Calcagno
Narghes Calcagno
OBOleg Butovsky
Oleg Butovsky

1 November 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
JMJakob Matschke
Jakob Matschke
MLMarc Lütgehetmann
Marc Lütgehetmann
CHChristian Hagel
Christian Hagel
JSJan P Sperhake
Jan P Sperhake
ASAnn Sophie Schröder
Ann Sophie Schröder
MGMarkus Glatzel
Markus Glatzel

1 November 2012 in Blood
Verified
Journal Article
Closed access
PDF file
MGMathias Gelderblom
Mathias Gelderblom
AWAnna Weymar
Anna Weymar
CBChristian Bernreuther
Christian Bernreuther
JVJoachim Velden
Joachim Velden
PAPriyadharshini Arunachalam
Priyadharshini Arunachalam
TMTim Magnus
Tim Magnus
The devastating effect of ischemic stroke is attenuated in mice lacking conventional and unconventional T cells, suggesting that inflammation enhances tissue damage in cerebral ischemia. We explored the functional role of αβ and γδ T cells in a murine model of stroke and distinguished 2 different T cell–dependent proinflammatory pathways in ischemia-reperfusion injury. IFN-γ produced by CD4+ T cells induced TNF-α production in macrophages, whereas IL-17A secreted by γδ T cells led to neutrophil recruitment. The synergistic effect of TNF-α and IL-17A on astrocytes resulted in enhanced secretion of CXCL-1, a neutrophil chemoattractant. Application of an IL-17A–blocking antibody within 3 hours after stroke induction decreased infarct size and improved neurologic outcome in the murine model. In autoptic brain tissue of patients who had a stroke, we detected IL-17A–positive lymphocytes, suggesting that this aspect of the inflammatory cascade is also relevant in the human brain. We propose that selective targeting of IL-17A signaling might provide a new therapeutic option for the treatment of stroke.

6 April 2010 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EJEllen Jorissen
Ellen Jorissen
JPJohannes Prox
Johannes Prox
CBChristian Bernreuther
Christian Bernreuther
SWSilvio Weber
Silvio Weber
RSRalf Schwanbeck
Ralf Schwanbeck
PSPaul Saftig
Paul Saftig
The metalloproteinase and major amyloid precursor protein (APP) α-secretase candidate ADAM10 is responsible for the shedding of proteins important for brain development, such as cadherins, ephrins, and Notch receptors.Adam10−/−mice die at embryonic day 9.5, due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generatedAdam10conditional knock-out (cKO) mice using a Nestin-Cre promotor, limiting ADAM10 inactivation to neural progenitor cells (NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells. Premature neuronal differentiation is associated with aberrant neuronal migration and a disorganized laminar architecture in the neocortex. Neurospheres derived fromAdam10cKO mice have a disrupted sphere organization and segregated more neurons at the expense of astrocytes. We found that Notch-1 processing was affected, leading to downregulation of several Notch-regulated genes inAdam10cKO brains, in accordance with the central role of ADAM10 in this signaling pathway and explaining the neurogenic phenotype. Finally, we found that α-secretase-mediated processing of APP was largely reduced in these neurons, demonstrating that ADAM10 represents the most important APP α-secretase in brain. Our study reveals that ADAM10 plays a central role in the developing brain by controlling mainly Notch-dependent pathways but likely also by reducing surface shedding of other neuronal membrane proteins including APP.

5 September 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
DFD Yang-Wei Fann
D Yang-Wei Fann
SLS-Y Lee
S-Y Lee
SMS Manzanero
S Manzanero
STS-C Tang
S-C Tang
MGM Gelderblom
M Gelderblom
TAT V Arumugam
T V Arumugam
Multi-protein complexes called inflammasomes have recently been identified and shown to contribute to cell death in tissue injury. Intravenous immunoglobulin (IVIg) is an FDA-approved therapeutic modality used for various inflammatory diseases. The objective of this study is to investigate dynamic responses of the NLRP1 and NLRP3 inflammasomes in stroke and to determine whether the NLRP1 and NLRP3 inflammasomes can be targeted with IVIg for therapeutic intervention. Primary cortical neurons were subjected to glucose deprivation (GD), oxygen–glucose deprivation (OGD) or simulated ischemia-reperfusion (I/R). Ischemic stroke was induced in C57BL/6J mice by middle cerebral artery occlusion, followed by reperfusion. Neurological assessment was performed, brain tissue damage was quantified, and NLRP1 and NLRP3 inflammasome protein levels were evaluated. NLRP1 and NLRP3 inflammasome components were also analyzed in postmortem brain tissue samples from stroke patients. Ischemia-like conditions increased the levels of NLRP1 and NLRP3 inflammasome proteins, and IL-1β and IL-18, in primary cortical neurons. Similarly, levels of NLRP1 and NLRP3 inflammasome proteins, IL-1β and IL-18 were elevated in ipsilateral brain tissues of cerebral I/R mice and stroke patients. Caspase-1 inhibitor treatment protected cultured cortical neurons and brain cells in vivo in experimental stroke models. IVIg treatment protected neurons in experimental stroke models by a mechanism involving suppression of NLRP1 and NLRP3 inflammasome activity. Our findings provide evidence that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke. We also identified NLRP1 and NLRP3 inflammasome inhibition as a novel mechanism by which IVIg can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that target inflammasome assembly and activity.

1 April 2018 in Developmental Cell
Verified
Journal Article
Closed access
GFGautier Follain
Gautier Follain
NONaël Osmani
Naël Osmani
AAAna Sofia Azevedo
Ana Sofia Azevedo
GAGuillaume Allio
Guillaume Allio
LMLuc Mercier
Luc Mercier
JGJacky G. Goetz
Jacky G. Goetz